What ESSA Pharma Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Glickman Richard M | Director | Oct 09 | Disposition to Issuer · D | −43,240 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Oct 09 | Tender Offer · U | −560,797 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Oct 09 | Tender Offer · U | −4,726,743 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Oct 09 | Tender Offer · U | −6,194,145 | — | — | 0 |
| Berger Franklin M | Director | Oct 09 | Disposition to Issuer · D | −784,404 | — | — | 0 |
| Thorell Marella | Director | Oct 09 | Disposition to Issuer · D | −2,881 | — | — | 0 |
| Martin John Alexander | Director | Oct 09 | Disposition to Issuer · D | −14,299 | — | — | 0 |
| Requadt Scott | Director | Oct 09 | Disposition to Issuer · D | −30,002 | — | — | 0 |
| Wood David S. | Chief Financial Officer | Oct 09 | Disposition to Issuer · D | −33,343 | — | — | 0 |
| Parkinson David Ross | President and CEO | Oct 09 | Disposition to Issuer · D | −65,675 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | Open-market sale · S | −11 | $1.88 | −$20.7 | 560,797 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | Open-market sale · S | −66 | $1.88 | −$124 | 4,726,743 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | Open-market sale · S | −79 | $1.88 | −$148 | 6,194,145 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | In/At-money Exercise · X | +203,336 | $0.00 | +$20.3 | 560,808 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | In/At-money Exercise · X | +1,235,030 | $0.00 | +$124 | 4,726,809 |
| Bvf Partners L P/IL | 10% owner | Aug 05 | In/At-money Exercise · X | +1,481,634 | $0.00 | +$148 | 6,194,224 |
| Biotech Growth N V | 10% owner | Nov 01 | Open-market sale · S | −1,879,583 | $1.51 | −$2.84M | 0 |
| Biotech Growth N V | 10% owner | Nov 01 | Open-market sale · S | −2,000,000 | $1.53 | −$3.06M | 1,879,583 |
| Biotech Growth N V | 10% owner | Nov 01 | Open-market sale · S | −2,000,000 | $1.53 | −$3.05M | 3,879,583 |
| Biotech Growth N V | 10% owner | Nov 01 | Open-market sale · S | −2,000,000 | $1.53 | −$3.06M | 5,879,583 |
Loading...
